Page 13 - Engager Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Innate Pharma SA: Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma

Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas Innate Pharma SA (Euronext

United statesArthur rouillHenry wheelerPierluigi porcuEuropean unionJefferson health philadelphiaEuropean medicines agencyDivision of hematologic malignanciesInternational conference on malignant lymphomaExchange commissionCompany annual report on formDrug administrationFrench financial markets authorityLymphoma study associationSidney kimmel cancer centerMycosis fungoides

Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides

Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomasMARSEILLE, France (BUSINESS WIRE) #ANKET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that inter.

United statesPierluigi porcuHenry wheelerDrug administrationJefferson health philadelphiaEuropean medicines agencySidney kimmel cancer centerLymphoma study associationFrench financial markets authorityExchange commissionDivision of hematologic malignanciesInternational conference on malignant lymphomaCompany annual report on formEuropean unionMycosis fungoidesInnate pharma

Innate Pharma SA: Innate Pharma Highlights Proprietary Tetra-specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congress

IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas

Eric vivierHenry wheelerArthur rouillCompany annual report on formExchange commissionEuropean hematology associationFrench financial markets authorityEuronext parisAntibody based natural killerEngager therapeuticsChief scientific officerInnate pharmaPrivate securities litigation reform actRisk factorsUniversal registration documentAnnual report

Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 C

IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET® platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomasIPH6501 is progressing towards a Phase 1 clinical trial in 2023MARSEILLE, France (BUSINESS WIRE) #ANKET Innate Ph.

Eric vivierHenry wheelerFrench financial markets authorityCompany annual report on formExchange commissionEuropean hematology associationInnate pharmaEuronext parisAntibody based natural killerEngager therapeuticsChief scientific officerPrivate securities litigation reform actRisk factorsUniversal registration documentAnnual report

Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress

Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Arthur rouillEric vivierHenry wheelerExchange commissionFrench financial markets authorityCompany annual report on formEuropean hematology associationEuronext parisAntibody based natural killerEngager therapeuticsChief scientific officerInnate pharmaPrivate securities litigation reform actRisk factorsUniversal registration documentAnnual report